What podcasts say about Merck
Every statement, with the speaker, the exact quote and the moment it was said.
What experts have said about Merck
19 statements · 16 positive · 3 mixed
Merck remains a good long-term holding.
“100% a good hold.”
Open the episode · NVIDIA Risk, Anthropic IPO Test, and Texas Roadhouse RallyListen at 9:16
Merck is attractive for investors bullish on the cancer-vaccine prospects.
“Merck is actually somewhat compelling here, I think, if you're actually bullish on the prospects.”
Open the episode · Tech Tumbles In Market Sell-Off… And Moderna’s Meltdown After Data Leak 10/22/26Listen at 28:48
Merck is currently performing very well
“I think that they are doing incredibly well.”
Open the episode · Mad Money w/ Jim Cramer 10/9/26Listen at 31:19
Merck is defensive and performs adequately during economic weakness.
“Merck's inherently defensive in nature. It does fine even in a bad economy.”
Open the episode · 'Mad Money w/ Jim Cramer 9/8/26Listen at 21:28
Merck shares rose about 2% and reached a fresh all-time high.
“it is extending those gains today up about 2% and touching a fresh all-time high earlier.”
Open the episode · Newmont Leads Mining Stocks, Ross Stores Gains, Merck Hits All-Time HighListen at 2:54
Merck gained about 2% and reached a fresh all-time high.
“it is extending those gains today up about 2% and touching a fresh all time high earlier.”
Open the episode · Newmont Leads Mining Stocks, Ross Stores Gains, Merck Hits All-Time HighListen at 3:22
Analysts have been raising their price targets for Merck.
“analysts have been boosting their price targets here on Merck.”
Open the episode · Newmont Leads Mining Stocks, Ross Stores Gains, Merck Hits All-Time HighListen at 4:00
Merck shares rose about 9% in premarket trading.
“And Merck is up about 9%.”
Open the episode · Moderna's Record Surge, Estee Lauder Rises on Q4 Beat, La-Z-Boy SinksListen at 0:46
Merck stock rose about 9%.
“Merck is up about 9%”
Open the episode · Moderna's Record Surge, Estee Lauder Rises on Q4 Beat, La-Z-Boy SinksListen at 1:09
Merck raised its full-year sales outlook.
“They boosted their sales outlook for the full year.”
Open the episode · Palantir Jumps; Spotify Dip; SpaceX ReportsListen at 1:54
Merck stock could recover to $120.
“I think he can manage its way all the way back to $120.”
Open the episode · Mad Money w/ Jim Cramer 5/1/26Listen at 9:48
Merck is attractive fundamentally but could fall another five points.
“I think that Merck is at 13 times earnings. I think Merck is terrific. I don't think that matters at all. I think the stock could drop another five.”
Open the episode · Mad Money w/ Jim Cramer 4/22/26Listen at 11:01
Merck is fundamentally attractive but could decline another five dollars.
“I think Merck is terrific. I don't think that matters at all. I think the stock could drop another five.”
Open the episode · Mad Money w/ Jim Cramer 4/22/26Listen at 11:04
Investors should buy some Merck while leaving room to add later.
“So you want to buy some and then leave. I like to say leave room.”
Open the episode · Mad Money w/ Jim Cramer 4/22/26Listen at 11:08
Merck’s ten key growth drivers represent 70% of its potential opportunity.
“Those alone account for 70% of the $70 billion I was referring to.”
Open the episode · Mad Money w/ Jim Cramer 2/3/26Listen at 34:12
Merck’s most-favored-nation agreement has a manageable financial impact.
“It does have impact, but it's manageable.”
Open the episode · Mad Money w/ Jim Cramer 2/3/26Listen at 39:18
Investors should sell into strength and rotate toward Merck.
“You've got to scale out to get into the best companies we have. You've got to scale out into companies like Merck”
Open the episode · Mad Money w/ Jim Cramer 12/4/25Listen at 23:10
“I think it could actually happen sooner than that, which is why I like the stock so much.”
Open the episode · Mad Money w/ Jim Cramer 12/4/25Listen at 26:52
Merck is undervalued relative to its strong drug pipeline.
“Merck's a very cheap stock that still doesn't even get nearly enough love for a terrific pipeline”
Open the episode · Mad Money w/ Jim Cramer 12/4/25Listen at 27:39
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.